Gene: OSBPL10

114884
ORP10|OSBP9
oxysterol binding protein like 10
protein-coding
3p23
Ensembl:ENSG00000144645 MIM:606738 Vega:OTTHUMG00000130672 UniprotKB:Q9BXB5
NC_000003.12
SNP Mapped
3   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.660e-1 (AD)  8.775e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2219250chr3:31776052 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs7612780chr3:31769066 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs2168422chr3:31763350 (GRCh38.p7)G>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PLCL20.945
NELL10.945
DCLK10.934
ERC20.931
FAR20.931
STAMBPL10.929
ATP8A20.928
GPR1580.928
MAPK130.927
PTPN30.924

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
STON2-0.604
COPZ2-0.602
MYOM1-0.596
HEY2-0.589
ASB4-0.589
YES1-0.578
CYP11A1-0.573
PARD3B-0.573
ROM1-0.565
MBNL3-0.561

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C0207389,10-dihydro-9,10-dihydroxybenzo(a)pyrene"9,10-dihydro-9,10-dihydroxybenzo(a)pyrene results in increased expression of OSBPL10 mRNA"26238291
D000082AcetaminophenAcetaminophen results in increased expression of OSBPL10 mRNA21420995|2906747
D000082AcetaminophenAcetaminophen affects the expression of OSBPL10 mRNA17562736
D020106AcrylamideAcrylamide results in increased expression of OSBPL10 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of OSBPL10 gene27153756
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of OSBPL10 mRNA22316170|2623829
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to OSBPL10 promoter]19654925
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of OSBPL10 mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of OSBPL10 mRNA"19150397
C006780bisphenol Abisphenol A results in decreased expression of OSBPL10 mRNA25181051
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of OSBPL10 mRNA28472532
D019327Copper SulfateCopper Sulfate results in increased expression of OSBPL10 mRNA19549813
D016572CyclosporineCyclosporine results in increased expression of OSBPL10 mRNA20106945|2556210
D003561CytarabineCytarabine results in decreased expression of OSBPL10 mRNA21198554
C014347decitabinedecitabine affects the expression of OSBPL10 mRNA23300844
D003907DexamethasoneDexamethasone results in decreased expression of OSBPL10 mRNA25047013
D002945CisplatinCisplatin affects the expression of OSBPL10 mRNA23300844
D002945CisplatinCisplatin results in decreased expression of OSBPL10 mRNA19561079
D004026DieldrinDieldrin results in increased expression of OSBPL10 mRNA28385952
D004317DoxorubicinOSBPL10 protein affects the susceptibility to Doxorubicin16217747
C118739entinostatentinostat results in increased expression of OSBPL10 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of OSBPL10 mRNA17555576
C069837fullerene C60fullerene C60 results in increased expression of OSBPL10 mRNA19167457
C410337K 7174K 7174 results in increased expression of OSBPL10 mRNA24086573
D008558MelphalanMelphalan results in decreased expression of OSBPL10 mRNA22363485
D008748MethylcholanthreneMethylcholanthrene promotes the reaction [AHR protein binds to OSBPL10 promoter]20348232
D016912Levonorgestrel[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of OSBPL10 mRNA19074003
D017239PaclitaxelOSBPL10 protein affects the susceptibility to Paclitaxel16217747
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of OSBPL10 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of OSBPL10 mRNA26272509
C006253pirinixic acidpirinixic acid affects the expression of OSBPL10 mRNA23811191
D011192Potassium DichromatePotassium Dichromate results in decreased expression of OSBPL10 mRNA23608068
D011441PropylthiouracilPropylthiouracil results in increased expression of OSBPL10 mRNA24780913
D011794QuercetinQuercetin results in increased expression of OSBPL10 mRNA21632981
C010792testosterone undecanoate[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of OSBPL10 mRNA19074003
C010792testosterone undecanoatetestosterone undecanoate results in increased expression of OSBPL10 mRNA19074003
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of OSBPL10 mRNA20106945|2163298
C009495titanium dioxidetitanium dioxide results in increased expression of OSBPL10 mRNA23557971
D014212TretinoinTretinoin results in increased expression of OSBPL10 mRNA23724009
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of OSBPL10 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of OSBPL10 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of OSBPL10 mRNA19101580|2317975
D014747VinblastineOSBPL10 protein affects the susceptibility to Vinblastine16217747
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA"27188386
C111237vorinostatvorinostat results in increased expression of OSBPL10 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001786phosphatidylserine binding-IDA23934110  
GO:0005548phospholipid transporter activity-TAS-  
GO:0008289lipid binding-IBA21873635  
GO:0015248sterol transporter activity-IBA21873635  
GO:0015485cholesterol binding-IBA21873635  
GO:0015485cholesterol binding-IDA17428193  
GO:0032934sterol binding-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0015914phospholipid transport-IEA-  
GO:0036150phosphatidylserine acyl-chain remodeling-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005794Golgi apparatus-IBA21873635  
GO:0005829cytosol-IBA21873635  
GO:0005829cytosol-TAS-  
GO:0005856cytoskeleton-IEA-  
GO:0016020membrane-IBA21873635  
GO:0043231intracellular membrane-bounded organelle-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1482801Acyl chain remodelling of PSTAS
R-HSA-1483206Glycerophospholipid biosynthesisTAS
R-HSA-1483257Phospholipid metabolismTAS
R-HSA-556833Metabolism of lipidsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal